Remove Adverse Reactions Remove Mayo Clinic Remove Vaccines
article thumbnail

Avatrombopag Receives FDA Approval for Treamtent of Pediatric Patients With Chronic Immune Thrompcytopenia

Pharmacy Times

Common adverse reactions in pediatric patients included viral infections, nasopharyngitis, and cough, but the drug was generally well-tolerated. In pediatric patients with persistent or chronic ITP, the most common adverse reactions (10% or more) included viral infection, nasopharyngitis, cough, pyrexia, and oropharyngeal pain.

article thumbnail

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Pharmacy Times

While no new adverse reactions were observed in this study, higher rates of hypersensitivity and infusion-related reactions were observed. Mayo Clinic. FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease. Eli Lilly and Company.

article thumbnail

Innovation in immuno-oncology: Leading companies in oncolytic viral proteins

Pharmaceutical Technology

A major strategy for OV development is genetic manipulation to weaken virus pathogenicity, enhance target selectivity, reduce adverse reactions, and/or insert exogenous therapeutic genes into the virus genome. OVs can be attenuated natural viruses or recombinant viruses.